<p>随着全球市场面临对人工智能估值和经济不确定性的担忧，亚洲市场也反映出这种谨慎情绪，尤其是在中国，投资者对人工智能相关股票的高估值感到担忧，抑制了风险偏好。在这样的环境下，识别被低估的股票可以成为投资者利用潜在市场低效的战略方法。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>盛达资源有限公司（SZSE:000603）</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch（KOSDAQ:A214450）</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>宁夏建材集团有限公司（SHSE:600449）</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>新西兰国王三文鱼投资（NZSE:NZK）</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>联创电子科技有限公司（SZSE:002036）</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD（NZSE:ERD）</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>中国儒意控股（SEHK:136）</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>北京小米科技（SHSE:688169）</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 277 只被低估亚洲股票的完整列表。</p>
<p>我们将查看我们筛选工具中的一些最佳选择。</p>
<h2>三养食品（KOSE:A003230）</h2>
<p><strong>概述：</strong> 三养食品有限公司及其子公司在韩国国内和国际上从事食品行业，市值为₩10.86 亿。</p>
<p><strong>运营：</strong> 抱歉，但提供的文本中似乎缺少收入细分的详细信息。如果您有该信息，我可以帮助您总结。</p>
<p><strong>公允价值的估计折扣：</strong> 48%</p>
<p>三养食品的交易价格为₩146 万，远低于其估计的公允价值₩280 万，表明其可能被低估。预计年收益增长 27.52%，年收入增长 22.3%，尽管与韩国市场相比，公司的收益增长较慢，但显示出强劲的增长潜力。最近在美国的合作，如与 bb.q Chicken 的合作，可能增强其全球品牌影响力和收入来源。</p>
<ul>
<li>我们的三养食品增长报告中的分析暗示未来财务表现强劲。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解三养食品的动态。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSE:A003230 截至 2025 年 11 月的折现现金流</p>
<h2>中国儒意控股（SEHK:136）</h2>
<p><strong>概述：</strong> 中国儒意控股有限公司是一家投资控股公司，涉及内容制作和在线流媒体业务，覆盖中国大陆、香港、欧洲及国际市场，市值为 HK$396.9 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其内容制作业务，产生了 CN¥648.86 百万，以及其在线流媒体和在线游戏业务，共同贡献了 CN¥34.4 亿。</p>
<p><strong>公允价值的估计折扣：</strong> 49.7%</p>
<p>中国儒意控股的交易价格为 HK$2.42，远低于其估计的公允价值 HK$4.81，表明基于现金流的潜在低估。预计年收益增长 25.54%，超过香港市场 11.6% 的增长率。尽管最近股东稀释，分析师一致认为潜在价格上涨 72.5%。然而，预计三年的股本回报率仍然温和，为 11.9%。</p>
<ul>
<li>我们编制的增长报告表明，中国儒意控股的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对中国儒意控股股票分析的全面见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:136 截至 2025 年 11 月的折现现金流</p>
<h2>荣昌生物（SEHK:9995）</h2>
<p><strong>概述：</strong> 荣昌生物有限公司是一家生物制药公司，专注于在中国大陆和美国发现、开发、生产和商业化生物药物，治疗自身免疫、肿瘤和眼科疾病，市值约为 HK$555.4 亿。</p>
<p><strong>运营：</strong> 荣昌生物的收入约为 CN¥22.3 亿，来自其生物制药研究、服务、生产和销售活动。</p>
<p><strong>公允价值的估计折扣：</strong> 17.2%</p>
<p>荣昌生物有限公司报告称，2025 年前九个月销售额为 CNY 17.2 亿，较去年同期的 CNY 12.1 亿有所增长，同时将净亏损减少至 CNY 5.507 亿，低于 CNY 10.7 亿。以 HK$90 的价格交易，低于其公允价值估计 HK$108.73，荣昌生物基于现金流被低估，预计未来三年年收入增长 27.4%，股本回报率预期高达 42.6%。</p>
<ul>
<li>我们精心准备的荣昌生物增长报告暗示其未来财务前景可能强于近期结果。</li>
<li>在这里深入了解荣昌生物的完整分析健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:9995 截至 2025 年 11 月的折现现金流</p>
<h2>抓住机会</h2>
<ul>
<li>点击此链接深入了解我们基于现金流的 277 家公司筛选器中的公司。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会，获取各市场无与伦比的股票分析。</li>
</ul>
<h2>寻找新的视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场动荡。</li>
<li>通过显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

荣昌生物

中国儒意

<p>亚洲市场面临人工智能估值担忧，投资者开始寻求被低估的股票。值得关注的股票包括三养食品、中国儒意控股和荣昌生物，这些股票的交易价格均低于估计的公允价值。三养食品与美国的合作显示出强劲的增长潜力。尽管股东稀释，中国儒意控股仍被低估，预计价格将上涨。荣昌生物报告了收入增长和净亏损减少，显示出未来的财务实力。Simply Wall St 提供投资分析和投资组合管理的工具</p>

<p>As global markets grapple with concerns over AI valuations and economic uncertainties, Asian markets have mirrored this cautious sentiment, particularly in China where investor worries about frothy valuations in AI-focused stocks have dampened risk appetite. In such an environment, identifying undervalued stocks can be a strategic approach for investors looking to capitalize on potential market inefficiencies.</p>
<div class="lb-trans"><p>随着全球市场面临对人工智能估值和经济不确定性的担忧，亚洲市场也反映出这种谨慎情绪，尤其是在中国，投资者对人工智能相关股票的高估值感到担忧，抑制了风险偏好。在这样的环境下，识别被低估的股票可以成为投资者利用潜在市场低效的战略方法。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Shengda ResourcesLtd (SZSE:000603)</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>Ningxia Building Materials GroupLtd (SHSE:600449)</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>New Zealand King Salmon Investments (NZSE:NZK)</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>LianChuang Electronic TechnologyLtd (SZSE:002036)</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD (NZSE:ERD)</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>China Ruyi Holdings (SEHK:136)</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>Beijing Roborock Technology (SHSE:688169)</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安国际医疗投资（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>盛达资源有限公司（SZSE:000603）</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch（KOSDAQ:A214450）</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>宁夏建材集团有限公司（SHSE:600449）</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>新西兰国王三文鱼投资（NZSE:NZK）</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>联创电子科技有限公司（SZSE:002036）</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD（NZSE:ERD）</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>中国儒意控股（SEHK:136）</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>北京小米科技（SHSE:688169）</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 277 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 277 只被低估亚洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看我们筛选工具中的一些最佳选择。</p>
</div><h2>Samyang Foods (KOSE:A003230)</h2>
<div class="lb-trans"><h2>三养食品（KOSE:A003230）</h2>
</div><p><strong>Overview:</strong> Samyang Foods Co., Ltd., along with its subsidiaries, operates in the food industry both domestically in South Korea and internationally, with a market cap of ₩10.86 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 三养食品有限公司及其子公司在韩国国内和国际上从事食品行业，市值为₩10.86 亿。</p>
</div><p><strong>Operations:</strong> I'm sorry, but it appears that the revenue segment details are missing from the provided text. If you have that information, I can help summarize it for you.</p>
<div class="lb-trans"><p><strong>运营：</strong> 抱歉，但提供的文本中似乎缺少收入细分的详细信息。如果您有该信息，我可以帮助您总结。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48%</p>
<div class="lb-trans"><p><strong>公允价值的估计折扣：</strong> 48%</p>
</div><p>Samyang Foods is trading at ₩1.46 million, significantly below its estimated fair value of ₩2.8 million, suggesting it may be undervalued based on cash flows. With earnings forecasted to grow 27.52% annually and revenue expected to increase by 22.3% per year, the company shows strong growth potential despite slower earnings growth compared to the Korean market. Recent collaborations in the U.S., like with bb.q Chicken, could enhance its global brand presence and revenue streams.</p>
<div class="lb-trans"><p>三养食品的交易价格为₩146 万，远低于其估计的公允价值₩280 万，表明其可能被低估。预计年收益增长 27.52%，年收入增长 22.3%，尽管与韩国市场相比，公司的收益增长较慢，但显示出强劲的增长潜力。最近在美国的合作，如与 bb.q Chicken 的合作，可能增强其全球品牌影响力和收入来源。</p>
</div><ul>
<li>The analysis detailed in our Samyang Foods growth report hints at robust future financial performance.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Samyang Foods.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的三养食品增长报告中的分析暗示未来财务表现强劲。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解三养食品的动态。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf?theme=light"/></p>
<p>KOSE:A003230 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>KOSE:A003230 截至 2025 年 11 月的折现现金流</p>
</div><h2>China Ruyi Holdings (SEHK:136)</h2>
<div class="lb-trans"><h2>中国儒意控股（SEHK:136）</h2>
</div><p><strong>Overview:</strong> China Ruyi Holdings Limited is an investment holding company involved in content production and online streaming across Mainland China, Hong Kong, Europe, and internationally with a market cap of HK$39.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中国儒意控股有限公司是一家投资控股公司，涉及内容制作和在线流媒体业务，覆盖中国大陆、香港、欧洲及国际市场，市值为 HK$396.9 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its content production business, which generated CN¥648.86 million, and its online streaming and online gaming businesses, which together contributed CN¥3.44 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其内容制作业务，产生了 CN¥648.86 百万，以及其在线流媒体和在线游戏业务，共同贡献了 CN¥34.4 亿。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.7%</p>
<div class="lb-trans"><p><strong>公允价值的估计折扣：</strong> 49.7%</p>
</div><p>China Ruyi Holdings is trading at HK$2.42, well below its estimated fair value of HK$4.81, indicating potential undervaluation based on cash flows. Earnings are projected to grow 25.54% annually, outpacing the Hong Kong market's growth rate of 11.6%. Despite recent shareholder dilution, analysts agree on a potential price increase of 72.5%. However, the forecasted return on equity remains modest at 11.9% over three years.</p>
<div class="lb-trans"><p>中国儒意控股的交易价格为 HK$2.42，远低于其估计的公允价值 HK$4.81，表明基于现金流的潜在低估。预计年收益增长 25.54%，超过香港市场 11.6% 的增长率。尽管最近股东稀释，分析师一致认为潜在价格上涨 72.5%。然而，预计三年的股本回报率仍然温和，为 11.9%。</p>
</div><ul>
<li>The growth report we've compiled suggests that China Ruyi Holdings' future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of China Ruyi Holdings stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，中国儒意控股的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对中国儒意控股股票分析的全面见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf?theme=light"/></p>
<p>SEHK:136 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:136 截至 2025 年 11 月的折现现金流</p>
</div><h2>RemeGen (SEHK:9995)</h2>
<div class="lb-trans"><h2>荣昌生物（SEHK:9995）</h2>
</div><p><strong>Overview:</strong> RemeGen Co., Ltd. is a biopharmaceutical company that focuses on discovering, developing, producing, and commercializing biological drugs for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$55.54 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 荣昌生物有限公司是一家生物制药公司，专注于在中国大陆和美国发现、开发、生产和商业化生物药物，治疗自身免疫、肿瘤和眼科疾病，市值约为 HK$555.4 亿。</p>
</div><p><strong>Operations:</strong> RemeGen generates revenue of approximately CN¥2.23 billion from its biopharmaceutical research, service, production, and sales activities.</p>
<div class="lb-trans"><p><strong>运营：</strong> 荣昌生物的收入约为 CN¥22.3 亿，来自其生物制药研究、服务、生产和销售活动。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 17.2%</p>
<div class="lb-trans"><p><strong>公允价值的估计折扣：</strong> 17.2%</p>
</div><p>RemeGen Co., Ltd. reported CNY 1.72 billion in sales for the first nine months of 2025, up from CNY 1.21 billion a year earlier, while reducing its net loss to CNY 550.7 million from CNY 1.07 billion. Trading at HK$90, below its fair value estimate of HK$108.73, RemeGen is undervalued based on cash flows with expected revenue growth of 27.4% annually over the next three years and a high forecasted return on equity of 42.6%.</p>
<div class="lb-trans"><p>荣昌生物有限公司报告称，2025 年前九个月销售额为 CNY 17.2 亿，较去年同期的 CNY 12.1 亿有所增长，同时将净亏损减少至 CNY 5.507 亿，低于 CNY 10.7 亿。以 HK$90 的价格交易，低于其公允价值估计 HK$108.73，荣昌生物基于现金流被低估，预计未来三年年收入增长 27.4%，股本回报率预期高达 42.6%。</p>
</div><ul>
<li>Our expertly prepared growth report on RemeGen implies its future financial outlook may be stronger than recent results.</li>
<li>Delve into the full analysis health report here for a deeper understanding of RemeGen.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们精心准备的荣昌生物增长报告暗示其未来财务前景可能强于近期结果。</li>
<li>在这里深入了解荣昌生物的完整分析健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf?theme=light"/></p>
<p>SEHK:9995 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:9995 截至 2025 年 11 月的折现现金流</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Click this link to deep-dive into the 277 companies within our Undervalued Asian Stocks Based On Cash Flows screener.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们基于现金流的 277 家公司筛选器中的公司。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会，获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新的视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场动荡。</li>
<li>通过显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

亚洲市场价值精选：三只交易价格低于预估价值的股票